Myriad Genetics, Inc (NASDAQ: MYGN) is -17.55% lower on its value in year-to-date trading and has touched a low of $16.10 and a high of $29.30 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MYGN stock was last observed hovering at around $16.17 in the last trading session, with the day’s loss setting it -0.39%.
Currently trading at $15.78, the stock is -21.47% and -33.97% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.13 million and changing -2.41% at the moment leaves the stock -33.27% off its SMA200. MYGN registered -4.31% loss for a year compared to 6-month loss of -36.01%. The firm has a 50-day simple moving average (SMA 50) of $23.9 and a 200-day simple moving average (SMA200) of $23.64895.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -34.20% gain in the last 1 month and extending the period to 3 months gives it a -43.34%, and is -10.19% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.21% over the week and 5.47% over the month.
Myriad Genetics, Inc (MYGN) has around 2700 employees, a market worth around $1.44B and $823.60M in sales. Fwd P/E is 113.88. Profit margin for the company is -14.08%. Distance from 52-week low is -1.99% and -46.14% from its 52-week high. The company has generated returns on investments over the last 12 months (-13.47%).
Myriad Genetics, Inc quarterly earnings per share for the current quarter are estimated at 0.03 with sales reaching $213.56M over the same period.The EPS is expected to grow by 147.01% this year, but quarterly earnings will post 11.60% year-over-year. Quarterly sales are estimated to grow 8.63% in year-over-year returns.
335.0 institutions hold shares in Myriad Genetics, Inc (MYGN), with institutional investors hold 105.81% of the company’s shares. The shares outstanding are 89.90M, and float is at 87.40M with Short Float at 5.13%. Institutions hold 103.68% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 15.15 million shares valued at $370.59 million. The investor’s holdings represent 18.5369 of the MYGN Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 10.06 million shares valued at $246.18 million to account for 12.314 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 8.26 million shares representing 10.109 and valued at over $202.1 million, while CAMBER CAPITAL MANAGEMENT LP holds 6.7292 of the shares totaling 5.5 million with a market value of $134.53 million.
Myriad Genetics, Inc (MYGN) Insider Activity
The most recent transaction is an insider sale by DIAZ PAUL J, the company’s President and CEO. SEC filings show that DIAZ PAUL J sold 15,000 shares of the company’s common stock on Oct 11 ’24 at a price of $22.93 per share for a total of $0.34 million. Following the sale, the insider now owns 0.96 million shares.
Still, SEC filings show that on Aug 21 ’24, Ancona Margaret (Officer) Proposed Sale 11,538 shares at an average price of $27.82 for $0.32 million. The insider now directly holds shares of Myriad Genetics, Inc (MYGN).
